%0 Journal Article
%A Lehtinen, Matti
%A van Damme, Pierre
%A Beddows, Simon
%A Pinto, Ligia A
%A Mariz, Filipe
%A Gray, Penelope
%A Dillner, Joakim
%T Scientific approaches to defining HPV vaccine-induced protective immunity.
%J International journal of cancer
%V 156
%N 10
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2025-00372
%P 1848-1857
%D 2025
%Z Division of Infections and Cancer,Deutsches Krebsforschungszentrum, /  2025 May 15;156(10):1848-1857 / AG Martin Müller
%X Seventeen years after the licensure of prophylactic human papillomavirus (HPV) L1 virus-like-particle vaccines, a defined antibody level that correlates with vaccine-induced protection against HPV infections and associated neoplasia is missing. In contrast, correlates of protection have been defined for many viral vaccines, including for the hepatitis B virus (HBV) vaccine. This review includes lessons learned from vaccination against HBV and the use of an established protective HBV surface antigen antibody level: 10 mIU/mL, an overview of HPV infection-induced and HPV vaccine-induced antibody responses, successful efforts to establish international standardization of serological reagents and associated tools, and 15-year vigilance of HPV vaccine-induced antibody levels in a vaccination cohort against breakthrough infections. This report identifies progress but also gaps on the journey toward the definition of a HPV vaccine-induced correlate of protection.
%K antibody (Other)
%K cancer (Other)
%K hepatitis B virus (Other)
%K human papillomavirus (Other)
%K vaccine (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39945620
%R 10.1002/ijc.35345
%U https://inrepo02.dkfz.de/record/298938